Combining immunotherapy with a tumor-targeted virus may help extend survival in some patients with recurrent glioblastoma, according to the results of a trial published in Nature Medicine.
Menu
Browsing: Patient Care
The location of a brain lesion could give clues as to whether or not it will cause seizures later on in life, according to the findings of a new multicenter study published in JAMA Neurology.
In its annual Best Hospitals rankings, U.S. News & World Report has once again recognized Northwestern Medicine hospitals as leaders in clinical excellence, and for the 12th consecutive year, Northwestern Memorial Hospital has been named to the Best Hospitals Honor Roll.
Mary McDermott, MD, ’92 GME, the Jeremiah Stamler Professor of Medicine in the Division of General Internal Medicine, has been awarded the American Heart Association 2023 Clinical Research Prize.
Administering broad-spectrum antibiotics before surgery to remove pancreas tumors may decrease the chances of surgical site infection, according to a recent study published in JAMA.
The Feinberg Academy of Medical Educators recently hosted Brian Garibaldi, MD, associate professor of Medicine at Johns Hopkins University, who visited Northwestern to lead a workshop and lecture on the importance of the physical exam as part of the TIME (Today’s Innovations in Medical Education) lecture series.
Northwestern Medicine investigators have shown that inhibiting a mutated gene can reduce seizure activity in adult-type diffuse gliomas, according to a study published in the Journal of Clinical Investigation.
From 1999 through 2020, Black Americans experienced more than 1.6 million excess deaths and more than 80 million excess years of life lost compared to white Americans, according to a recent study published in JAMA.
An informational communications tool provided to patients with dilated cardiomyopathy helped increase cardiovascular screenings in their first-degree relatives who have a higher risk of developing the genetic disease, according to findings published in Circulation.
Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery, according to a recent study published in Nature Medicine.